Annual CFO
-$12.18 M
+$12.83 M+51.31%
December 31, 2023
Summary
- As of February 26, 2025, APRE annual cash flow from operations is -$12.18 million, with the most recent change of +$12.83 million (+51.31%) on December 31, 2023.
- During the last 3 years, APRE annual CFO has risen by +$29.63 million (+70.87%).
Performance
APRE Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$2.47 M
+$1.17 M+32.22%
September 30, 2024
Summary
- As of February 26, 2025, APRE quarterly cash flow from operations is -$2.47 million, with the most recent change of +$1.17 million (+32.22%) on September 30, 2024.
- Over the past year, APRE quarterly CFO has increased by +$1.47 million (+37.29%).
- APRE quarterly CFO is now -10.09% below its all-time high of -$2.24 million, reached on September 30, 2023.
Performance
APRE Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$13.79 M
-$226.30 K-1.67%
September 30, 2024
Summary
- As of February 26, 2025, APRE TTM cash flow from operations is -$13.79 million, with the most recent change of -$226.30 thousand (-1.67%) on September 30, 2024.
- Over the past year, APRE TTM CFO has dropped by -$651.00 thousand (-4.96%).
- APRE TTM CFO is now -228.44% below its all-time high of -$4.20 million, reached on March 31, 2019.
Performance
APRE TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
APRE Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +51.3% | +37.3% | -5.0% |
| 3 y3 years | +70.9% | +70.0% | +66.1% |
| 5 y5 years | +20.1% | +11.6% | +48.4% |
APRE Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +67.7% | -10.1% | +75.8% | -13.2% | +63.4% |
| 5 y | 5-year | at high | +70.9% | -10.1% | +83.3% | -13.2% | +69.9% |
| alltime | all time | <-9999.0% | +70.9% | -10.1% | +83.3% | -228.4% | +69.9% |
Aprea Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$2.47 M(-32.2%) | -$13.79 M(+1.7%) |
| Jun 2024 | - | -$3.64 M(-7.5%) | -$13.56 M(+3.2%) |
| Mar 2024 | - | -$3.94 M(+5.2%) | -$13.13 M(+7.9%) |
| Dec 2023 | -$12.18 M(-51.3%) | -$3.74 M(+66.8%) | -$12.18 M(-2.3%) |
| Sep 2023 | - | -$2.24 M(-30.3%) | -$12.46 M(-25.9%) |
| Jun 2023 | - | -$3.22 M(+8.0%) | -$16.81 M(-25.3%) |
| Mar 2023 | - | -$2.98 M(-25.9%) | -$22.49 M(-10.1%) |
| Dec 2022 | -$25.01 M(-33.6%) | -$4.02 M(-39.0%) | -$25.01 M(-19.8%) |
| Sep 2022 | - | -$6.59 M(-25.9%) | -$31.17 M(-5.0%) |
| Jun 2022 | - | -$8.90 M(+62.0%) | -$32.81 M(+3.6%) |
| Mar 2022 | - | -$5.50 M(-46.0%) | -$31.66 M(-16.0%) |
| Dec 2021 | -$37.69 M | -$10.18 M(+23.6%) | -$37.69 M(-7.4%) |
| Sep 2021 | - | -$8.23 M(+6.2%) | -$40.71 M(-7.3%) |
| Jun 2021 | - | -$7.75 M(-32.7%) | -$43.90 M(-4.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2021 | - | -$11.52 M(-12.7%) | -$45.78 M(+9.5%) |
| Dec 2020 | -$41.80 M(+56.5%) | -$13.20 M(+15.5%) | -$41.80 M(-3.6%) |
| Sep 2020 | - | -$11.42 M(+18.5%) | -$43.35 M(+24.9%) |
| Jun 2020 | - | -$9.64 M(+27.8%) | -$34.72 M(+15.5%) |
| Mar 2020 | - | -$7.54 M(-48.8%) | -$30.05 M(+12.5%) |
| Dec 2019 | -$26.71 M(+75.1%) | -$14.74 M(+427.8%) | -$26.71 M(+123.2%) |
| Sep 2019 | - | -$2.79 M(-43.9%) | -$11.97 M(+30.5%) |
| Jun 2019 | - | -$4.98 M(+18.5%) | -$9.17 M(+118.5%) |
| Mar 2019 | - | -$4.20 M | -$4.20 M |
| Dec 2018 | -$15.25 M(+8.9%) | - | - |
| Dec 2017 | -$14.00 M(+637.8%) | - | - |
| Jun 2008 | -$1.90 M(+49.6%) | - | - |
| Jun 2007 | -$1.27 M(-36.6%) | - | - |
| Jun 2006 | -$2.00 M(<-9900.0%) | - | - |
| Dec 2004 | $0.00 | - | - |
FAQ
- What is Aprea Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Aprea Therapeutics?
- What is Aprea Therapeutics annual CFO year-on-year change?
- What is Aprea Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Aprea Therapeutics?
- What is Aprea Therapeutics quarterly CFO year-on-year change?
- What is Aprea Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Aprea Therapeutics?
- What is Aprea Therapeutics TTM CFO year-on-year change?
What is Aprea Therapeutics annual cash flow from operations?
The current annual CFO of APRE is -$12.18 M
What is the all time high annual CFO for Aprea Therapeutics?
Aprea Therapeutics all-time high annual cash flow from operations is $0.00
What is Aprea Therapeutics annual CFO year-on-year change?
Over the past year, APRE annual cash flow from operations has changed by +$12.83 M (+51.31%)
What is Aprea Therapeutics quarterly cash flow from operations?
The current quarterly CFO of APRE is -$2.47 M
What is the all time high quarterly CFO for Aprea Therapeutics?
Aprea Therapeutics all-time high quarterly cash flow from operations is -$2.24 M
What is Aprea Therapeutics quarterly CFO year-on-year change?
Over the past year, APRE quarterly cash flow from operations has changed by +$1.47 M (+37.29%)
What is Aprea Therapeutics TTM cash flow from operations?
The current TTM CFO of APRE is -$13.79 M
What is the all time high TTM CFO for Aprea Therapeutics?
Aprea Therapeutics all-time high TTM cash flow from operations is -$4.20 M
What is Aprea Therapeutics TTM CFO year-on-year change?
Over the past year, APRE TTM cash flow from operations has changed by -$651.00 K (-4.96%)